



**招商永隆銀行**  
CMB WING LUNG BANK

**Regulatory Disclosures**

**Main Features of Regulatory Capital Instruments**

**As at 24 January 2024**

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments

The following disclosures are made in accordance with Section 16FE of the Banking (Disclosures) Rules issued by the Hong Kong Monetary Authority (“HKMA”) following the issuance of the US\$500 million undated non-cumulative subordinated additional tier 1 capital securities on 27 December 2023 and the redemption of the US\$400 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 24 January 2019) on 24 January 2024.

The regulatory capital instruments included in the Bank’s consolidated capital base as at 24 January 2024 are as follows:

1. Common Equity Tier 1 Capital (Ordinary share capital)
2. US\$260 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 December 2019)
3. RMB1,000 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 February 2020)
4. US\$200 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 23 March 2022)
5. US\$500 million undated non-cumulative subordinated Additional Tier 1 capital securities (issued on 27 December 2023)

The main features of the regulatory capital instruments are set out in the following sections. Full terms and conditions, which are available in English only, are published on the Bank’s website at [http://www.cmbwinglungbank.com/wlb\\_corporate/en/about-us/investor-communication/capital-instruments-issued-terms\\_20240124.html](http://www.cmbwinglungbank.com/wlb_corporate/en/about-us/investor-communication/capital-instruments-issued-terms_20240124.html)

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 1. Common Equity Tier 1 Capital (Ordinary share capital)

|    |  | (a)  |
|----|--|--|
|    |  | Quantitative / qualitative information         |
| 1  | Issuer   | CMB Wing Lung Bank Limited                     |
| 2  | Unique identifier (e.g. CUSIP, ISIN or Bloomberg identifier for private placement)               | N/A  |
| 3  | Governing law(s) of the instrument   | Law of Hong Kong Special Administrative Region |
|    | <i>Regulatory treatment</i>  |  |
| 4  | Transitional Basel III rules #   | Common Equity Tier 1                           |
| 5  | Post-transitional Basel III rules +  | Common Equity Tier 1                           |
| 6  | Eligible at solo / group / solo and group  | Solo and group                                 |
| 7  | Instrument type (types to be specified by each jurisdiction)                                     | Ordinary shares                                |
| 8  | Amount recognised in regulatory capital (currency in millions, as of most recent reporting date) | HK\$1,161 million as at 24 January 2024        |
| 9  | Par value of instrument  | N/A  |
| 10 | Accounting classification  | Shareholders' equity                           |
| 11 | Original date of issuance  | Since incorporation                            |
| 12 | Perpetual or dated   | Perpetual                                      |
| 13 | Original maturity date   | No maturity                                    |
| 14 | Issuer call subject to prior supervisory approval  | N/A  |
| 15 | Optional call date, contingent call dates and redemption amount                                  | N/A  |
| 16 | Subsequent call dates, if applicable   | N/A  |
|    | <i>Coupons / dividends</i>   |  |
| 17 | Fixed or floating dividend / coupon  | Discretionary dividend amount                  |
| 18 | Coupon rate and any related index  | N/A  |
| 19 | Existence of a dividend stopper  | N/A  |
| 20 | Fully discretionary, partially discretionary or mandatory  | Fully discretionary                            |
| 21 | Existence of step-up or other incentive to redeem  | N/A  |
| 22 | Non-cumulative or cumulative   | N/A  |
| 23 | Convertible or non-convertible   | N/A  |
| 24 | If convertible, conversion trigger(s)  | N/A  |
| 25 | If convertible, fully or partially   | N/A  |
| 26 | If convertible, conversion rate  | N/A  |
| 27 | If convertible, mandatory or optional conversion   | N/A  |
| 28 | If convertible, specify instrument type convertible into   | N/A  |
| 29 | If convertible, specify issuer of instrument it converts into                                    | N/A  |
| 30 | Write-down feature   | N/A  |
| 31 | If write-down, write-down trigger(s)   | N/A  |
| 32 | If write-down, full or partial   | N/A  |
| 33 | If write-down, permanent or temporary  | N/A  |
| 34 | If temporary write-down, description of write-up mechanism                                       | N/A  |

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 1. Common Equity Tier 1 Capital (Ordinary share capital) (continued)

|    |   | (a)  |
|----|---|--|
|    |   | Quantitative / qualitative information                           |
| 35 | Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument in the insolvency creditor hierarchy of the legal entity concerned). | Non-cumulative subordinated additional tier 1 capital securities |
| 36 | Non-compliant transitioned features   | N/A  |
| 37 | If yes, specify non-compliant features  | N/A  |

# Regulatory treatment of capital instruments subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.

+ Regulatory treatment of capital instruments not subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 2. US\$260 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 December 2019)

|                             |  | (a)  |
|-----------------------------|--|--|
|                             |  | Quantitative / qualitative information   |
| 1                           | Issuer   | CMB Wing Lung Bank Limited   |
| 2                           | Unique identifier (e.g. CUSIP, ISIN or Bloomberg identifier for private placement)               | N/A  |
| 3                           | Governing law(s) of the instrument   | Law of Hong Kong Special Administrative Region   |
| <i>Regulatory treatment</i> |  |  |
| 4                           | Transitional Basel III rules #   | N/A  |
| 5                           | Post-transitional Basel III rules +  | Additional Tier 1  |
| 6                           | Eligible at solo / group / solo and group  | Solo and group   |
| 7                           | Instrument type (types to be specified by each jurisdiction)                                     | Undated Non-Cumulative Subordinated Capital Securities   |
| 8                           | Amount recognised in regulatory capital (currency in millions, as of most recent reporting date) | US\$260 million as at 24 January 2024  |
| 9                           | Par value of instrument  | US\$260 million  |
| 10                          | Accounting classification  | Equity - par value   |
| 11                          | Original date of issuance  | 27 December 2019   |
| 12                          | Perpetual or dated   | Perpetual  |
| 13                          | Original maturity date   | No maturity  |
| 14                          | Issuer call subject to prior supervisory approval  | Yes  |
| 15                          | Optional call date, contingent call dates and redemption amount                                  | Optional redemption date: 27 December 2024 (First Call Date)<br>Redemption for taxation reasons: Yes<br>Redemption for regulatory reasons: Yes<br>Redemption price: Redeemed at the outstanding principal amount together with distributions accrued to the date of redemption, subject to adjustment following the occurrence of a Non-Viability Event.   |
| 16                          | Subsequent call dates, if applicable   | Any Distribution Payment Date after the First Call Date  |
| <i>Coupons / dividends</i>  |  |  |
| 17                          | Fixed or floating dividend / coupon  | Fixed  |
| 18                          | Coupon rate and any related index  | 5.23 per cent per annum for the period from, and including, the Issue Date to, but excluding the First Call Date. The then prevailing 5 year U.S. Treasury Rate plus 350 bps for the period from, and including, the First Call Date and each Distribution Reset Date thereafter to, but excluding, the immediately following Distribution Reset Date.<br><br>Any distributions are subject to there being no Mandatory Distribution Cancellation Event or Optional Distribution Cancellation Event. |
| 19                          | Existence of a dividend stopper  | Yes  |
| 20                          | Fully discretionary, partially discretionary or mandatory  | Fully discretionary  |
| 21                          | Existence of step-up or other incentive to redeem  | No   |

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 2. US\$260 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 December 2019) (continued)

|    |   | (a)  |
|----|---|--|
|    |   | Quantitative / qualitative information   |
| 22 | Non-cumulative or cumulative                                  | Non-cumulative   |
| 23 | Convertible or non-convertible                                | Non-convertible  |
| 24 | If convertible, conversion trigger(s)                         | N/A  |
| 25 | If convertible, fully or partially                            | N/A  |
| 26 | If convertible, conversion rate                               | N/A  |
| 27 | If convertible, mandatory or optional conversion              | N/A  |
| 28 | If convertible, specify instrument type convertible into      | N/A  |
| 29 | If convertible, specify issuer of instrument it converts into | N/A  |
| 30 | Write-down feature  | Yes  |
| 31 | If write-down, write-down trigger(s)                          | <p>If a Non-Viability Event occurs and is continuing, the Issuer shall, by the provision of a Non-Viability Event Notice, irrevocably reduce the then principal amount of, and cancel any accrued but unpaid distribution in respect of, each Capital Security in whole or in part.</p> <p>"Non-Viability Event" means the earlier of:</p> <p>(a) the HKMA notifying the Issuer in writing that the HKMA is of the opinion that a write-off or conversion is necessary, without which the Issuer would become non-viable; or</p> <p>(b) the HKMA notifying the Issuer in writing that a decision has been made by the government body, a government officer or other relevant regulatory body with the authority to make such a decision, that a public sector injection of capital or equivalent support is necessary, without which the Issuer would become non-viable.</p> <p>The Capital Securities may be written off, cancelled, converted or modified, or the form of the Capital Securities may be changed, in the exercise of any Hong Kong Resolution Authority Power under the Financial Institutions (Resolution) Ordination (Cap. 628) of Hong Kong by the relevant Hong Kong Resolution Authority without prior notice and which may include (without limitation) and result in any of the following or some combination thereof:</p> <p>(a) the reduction or cancellation of all or a part of the principal amount of, or Distributions on, the Capital Securities;</p> |

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 2. US\$260 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 December 2019) (continued)

|    |   | (a)  |
|----|---|--|
|    |   | Quantitative / qualitative information   |
| 31 | If write-down, write-down trigger(s)  | (b) the conversion of all or a part of the principal amount of, or Distributions on, the Capital Securities into shares or other securities or other obligations of the Issuer or another person (and the issue to or conferral on the holder of such shares, securities or obligations), including by means of an amendment, modification or variation of the terms of the Capital Securities; and<br><br>(c) the amendment or alteration of the maturity of the Capital Securities or amendment or alteration of the amount of Distributions payable on the Capital Securities, or the date on which the Distributions become payable, including by suspending payment for a temporary period, or any other amendment or alteration of the terms and conditions of the Capital Securities. |
| 32 | If write-down, full or partial  | Full or partial  |
| 33 | If write-down, permanent or temporary   | Permanent  |
| 34 | If temporary write-down, description of write-up mechanism  | N/A  |
| 35 | Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument in the insolvency creditor hierarchy of the legal entity concerned). | Subordinate to the claims of:<br>(a) all unsubordinated creditors of the Issuer (including its depositors);<br>(b) creditors in respect of Tier 2 Capital Instruments of the Issuer; and<br>(c) all other Subordinated Creditors of the Issuer whose claims are stated to rank senior to the Capital Securities or rank senior to the Capital Securities by operation of law or contract.  |
| 36 | Non-compliant transitioned features   | No   |
| 37 | If yes, specify non-compliant features  | N/A  |

# Regulatory treatment of capital instruments subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.

+ Regulatory treatment of capital instruments not subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 3. RMB1,000 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 February 2020)

|    |  | (a)   |
|----|--|---|
|    |  | Quantitative / qualitative information  |
| 1  | Issuer   | CMB Wing Lung Bank Limited  |
| 2  | Unique identifier (e.g. CUSIP, ISIN or Bloomberg identifier for private placement)               | N/A   |
| 3  | Governing law(s) of the instrument   | Law of Hong Kong Special Administrative Region  |
|    | <i>Regulatory treatment</i>  |   |
| 4  | Transitional Basel III rules #   | N/A   |
| 5  | Post-transitional Basel III rules +  | Additional Tier 1   |
| 6  | Eligible at solo / group / solo and group  | Solo and group  |
| 7  | Instrument type (types to be specified by each jurisdiction)                                     | Undated Non-Cumulative Subordinated Capital Securities  |
| 8  | Amount recognised in regulatory capital (currency in millions, as of most recent reporting date) | RMB1,000 million as at 24 January 2024  |
| 9  | Par value of instrument  | RMB1,000 million  |
| 10 | Accounting classification  | Equity - par value  |
| 11 | Original date of issuance  | 27 February 2020  |
| 12 | Perpetual or dated   | Perpetual   |
| 13 | Original maturity date   | No maturity   |
| 14 | Issuer call subject to prior supervisory approval  | Yes   |
| 15 | Optional call date, contingent call dates and redemption amount                                  | Optional redemption date: 27 February 2025 (First Call Date)<br>Redemption for taxation reasons: Yes<br>Redemption for regulatory reasons: Yes<br>Redemption price: Redeemed at the outstanding principal amount together with distributions accrued to the date of redemption, subject to adjustment following the occurrence of a Non-Viability Event.  |
| 16 | Subsequent call dates, if applicable   | Any Distribution Payment Date after the First Call Date   |
|    | <i>Coupons / dividends</i>   |   |
| 17 | Fixed or floating dividend / coupon  | Fixed   |
| 18 | Coupon rate and any related index  | 4.78 per cent per annum for the period from, and including, the Issue Date to, but excluding the Distribution Payment Date falling on or nearest to the First Call Date. The then prevailing rate of 5 year Chinese government notes plus 212 bps for the period from, and including, the First Call Date and each Distribution Reset Date thereafter to, but excluding, the immediately following Distribution Reset Date.<br><br>Any distributions are subject to there being no Mandatory Distribution Cancellation Event or Optional Distribution Cancellation Event. |
| 19 | Existence of a dividend stopper  | Yes   |
| 20 | Fully discretionary, partially discretionary or mandatory  | Fully discretionary   |



# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 3. RMB1,000 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 February 2020) (continued)

|    |   | (a)   |
|----|---|---|
|    |   | Quantitative / qualitative information  |
| 21 | Existence of step-up or other incentive to redeem             | No  |
| 22 | Non-cumulative or cumulative                                  | Non-cumulative  |
| 23 | Convertible or non-convertible                                | Non-convertible   |
| 24 | If convertible, conversion trigger(s)                         | N/A   |
| 25 | If convertible, fully or partially                            | N/A   |
| 26 | If convertible, conversion rate                               | N/A   |
| 27 | If convertible, mandatory or optional conversion              | N/A   |
| 28 | If convertible, specify instrument type convertible into      | N/A   |
| 29 | If convertible, specify issuer of instrument it converts into | N/A   |
| 30 | Write-down feature  | Yes   |
| 31 | If write-down, write-down trigger(s)                          | <p>If a Non-Viability Event occurs and is continuing, the Issuer shall, by the provision of a Non-Viability Event Notice, irrevocably reduce the then principal amount of, and cancel any accrued but unpaid distribution in respect of, each Capital Security in whole or in part.</p> <p>"Non-Viability Event" means the earlier of:</p> <p>(a) the HKMA notifying the Issuer in writing that the HKMA is of the opinion that a write-off or conversion is necessary, without which the Issuer would become non-viable; or</p> <p>(b) the HKMA notifying the Issuer in writing that a decision has been made by the government body, a government officer or other relevant regulatory body with the authority to make such a decision, that a public sector injection of capital or equivalent support is necessary, without which the Issuer would become non-viable.</p> <p>The Capital Securities may be written off, cancelled, converted or modified, or the form of the Capital Securities may be changed, in the exercise of any Hong Kong Resolution Authority Power under the Financial Institutions (Resolution) Ordination (Cap. 628) of Hong Kong by the relevant Hong Kong Resolution Authority without prior notice and which may include (without limitation) and result in any of the following or some combination thereof:</p> <p>(a) the reduction or cancellation of all or a part of the principal amount of, or Distributions on, the Capital Securities;</p> <p>(b) the conversion of all or a part of the principal amount of, or Distributions on, the Capital Securities into shares or other securities or other obligations of the Issuer or another person (and the issue to or conferral on the holder of such shares, securities or obligations), including by means of an amendment, modification or variation of the terms of the Capital Securities; and</p> |

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 3. RMB1,000 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 February 2020) (continued)

|    |   | (a)   |
|----|---|---|
|    |   | Quantitative / qualitative information  |
| 31 | If write-down, write-down trigger(s)  | (c) the amendment or alteration of the maturity of the Capital Securities or amendment or alteration of the amount of Distributions payable on the Capital Securities, or the date on which the Distributions become payable, including by suspending payment for a temporary period, or any other amendment or alteration of the terms and conditions of the Capital Securities.         |
| 32 | If write-down, full or partial  | Full or partial   |
| 33 | If write-down, permanent or temporary   | Permanent   |
| 34 | If temporary write-down, description of write-up mechanism  | N/A   |
| 35 | Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument in the insolvency creditor hierarchy of the legal entity concerned). | Subordinate to the claims of:<br>(a) all unsubordinated creditors of the Issuer (including its depositors);<br>(b) creditors in respect of Tier 2 Capital Instruments of the Issuer; and<br>(c) all other Subordinated Creditors of the Issuer whose claims are stated to rank senior to the Capital Securities or rank senior to the Capital Securities by operation of law or contract. |
| 36 | Non-compliant transitioned features   | No  |
| 37 | If yes, specify non-compliant features  | N/A   |

# Regulatory treatment of capital instruments subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.

+ Regulatory treatment of capital instruments not subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 4. US\$200 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 23 March 2022)

|                             |  | (a)   |
|-----------------------------|--|---|
|                             |  | Quantitative / qualitative information  |
| 1                           | Issuer   | CMB Wing Lung Bank Limited  |
| 2                           | Unique identifier (e.g. CUSIP, ISIN or Bloomberg identifier for private placement)               | N/A   |
| 3                           | Governing law(s) of the instrument   | Hong Kong Laws (subordination governed by Laws of Hong Kong Special Administrative Region)  |
| <i>Regulatory treatment</i> |  |   |
| 4                           | Transitional Basel III rules #   | N/A   |
| 5                           | Post-transitional Basel III rules +  | Additional Tier 1   |
| 6                           | Eligible at solo / group / solo and group  | Solo and group  |
| 7                           | Instrument type (types to be specified by each jurisdiction)                                     | Undated Non-Cumulative Subordinated Additional Tier 1 Capital Securities  |
| 8                           | Amount recognised in regulatory capital (currency in millions, as of most recent reporting date) | US\$200 million as at 24 January 2024   |
| 9                           | Par value of instrument  | US\$200 million   |
| 10                          | Accounting classification  | Equity - par value  |
| 11                          | Original date of issuance  | 23 March 2022   |
| 12                          | Perpetual or dated   | Perpetual   |
| 13                          | Original maturity date   | No maturity   |
| 14                          | Issuer call subject to prior supervisory approval  | Yes   |
| 15                          | Optional call date, contingent call dates and redemption amount                                  | <ul style="list-style-type: none"> <li>- 23 March 2027 (First Call Date)</li> <li>- No fixed redemption date</li> <li>- Optional Redemption (on a designated date on 23 March 2027 or on any Distribution Payment Date thereafter), Tax or Regulatory Redemption are all subject to prior written consent of the HKMA and satisfying any conditions that the HKMA may impose at that time. Redemption amount will be the outstanding principal amount together (if appropriate) with distributions accrued to (but excluding) the date of redemption, subject to adjustment following the occurrence of a Non-Viability Event.</li> </ul> |
| 16                          | Subsequent call dates, if applicable   | Any Distribution Payment Date after the First Call Date   |
| <i>Coupons / dividends</i>  |  |   |
| 17                          | Fixed or floating dividend / coupon  | Fixed   |

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 4. US\$200 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 23 March 2022) (continued)

|    |   |  |
|----|---|--|
| 18 | Coupon rate and any related index                             | At a fixed rate of 3.34% per annum for the period from, and including, the Issue Date to, but excluding the First Call Date. On the First Call Date and each anniversary falling five years thereafter, the Distribution Rate will reset by reference to the then-prevailing five year U.S. Treasury Rate plus 149 bps per annum.<br><br>Any distributions are subject to there being no Mandatory Distribution Cancellation Event or Optional Distribution Cancellation Event.  |
| 19 | Existence of a dividend stopper                               | Yes  |
| 20 | Fully discretionary, partially discretionary or mandatory     | Fully discretionary  |
| 21 | Existence of step-up or other incentive to redeem             | No   |
| 22 | Non-cumulative or cumulative                                  | Non-cumulative   |
| 23 | Convertible or non-convertible                                | Non-convertible  |
| 24 | If convertible, conversion trigger(s)                         | N/A  |
| 25 | If convertible, fully or partially                            | N/A  |
| 26 | If convertible, conversion rate                               | N/A  |
| 27 | If convertible, mandatory or optional conversion              | N/A  |
| 28 | If convertible, specify instrument type convertible into      | N/A  |
| 29 | If convertible, specify issuer of instrument it converts into | N/A  |
| 30 | Write-down feature  | Yes  |
| 31 | If write-down, write-down trigger(s)                          | If a Non-Viability Event occurs and is continuing, the Issuer shall, by the provision of a Non-Viability Event Notice, irrevocably reduce the then prevailing principal amount of, and cancel any accrued but unpaid distribution in respect of, each Capital Security in whole or in part.<br><br>"Non-Viability Event" means the earlier of:<br>(a) the HKMA notifying the Issuer in writing that the HKMA is of the opinion that a write-off or conversion is necessary, without which the Issuer would become non-viable; and<br>(b) the HKMA notifying the Issuer in writing that a decision has been made by the government body, a government officer or other relevant regulatory body with the authority to make such a decision, that a public sector injection of capital or equivalent support is necessary, without which the Issuer would become non-viable. |

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 4. US\$200 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 23 March 2022) (continued)

|    |   | (a)   |
|----|---|---|
|    |   | Quantitative / qualitative information  |
| 31 | If write-down, write-down trigger(s)  | <p>The Capital Securities may be written off, cancelled, converted or modified, or the form of the Capital Securities may be changed, in the exercise of any Hong Kong Resolution Authority Power under the Financial Institutions (Resolution) Ordinance (Cap. 628) of Hong Kong by the relevant Hong Kong Resolution Authority without prior notice and which may include (without limitation) and result in any of the following or some combination thereof:</p> <p>(a) the reduction or cancellation of all or a part of the principal amount of, or Distributions on, the Capital Securities;</p> <p>(b) the conversion of all or a part of the principal amount of, or Distributions on, the Capital Securities into shares or other securities or other obligations of the Issuer or another person (and the issue to or conferral on the holder of such shares, securities or obligations), including by means of an amendment, modification or variation of the terms of the Capital Securities; and</p> <p>(c) the amendment or alteration of the maturity of the Capital Securities or amendment or alteration of the amount of Distributions payable on the Capital Securities, or the date on which the Distributions become payable, including by suspending payment for a temporary period, or any other amendment or alteration of the terms and conditions of the Capital Securities.</p> |
| 32 | If write-down, full or partial  | Full or partial   |
| 33 | If write-down, permanent or temporary   | Permanent   |
| 34 | If temporary write-down, description of write-up mechanism  | N/A   |
| 35 | Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument in the insolvency creditor hierarchy of the legal entity concerned). | <p>Subordinate to the claims of:</p> <p>(a) all unsubordinated creditors of the Issuer (including its depositors);</p> <p>(b) creditors in respect of Tier 2 Capital Securities of the Issuer; and</p> <p>(c) all other Subordinated Creditors of the Issuer whose claims are stated to rank senior to the Capital Securities or rank senior to the Capital Securities by operation of law or contract.</p>   |
| 36 | Non-compliant transitioned features   | No  |
| 37 | If yes, specify non-compliant features  | N/A   |

# Regulatory treatment of capital instruments subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.

+ Regulatory treatment of capital instruments not subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 5. US\$500 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 December 2023)

|    |  | (a)   |
|----|--|---|
|    |  | Quantitative / qualitative information  |
| 1  | Issuer   | CMB Wing Lung Bank Limited  |
| 2  | Unique identifier (e.g. CUSIP, ISIN or Bloomberg identifier for private placement)               | N/A   |
| 3  | Governing law(s) of the instrument   | Hong Kong Laws (subordination governed by Laws of Hong Kong Special Administrative Region)  |
|    | <i>Regulatory treatment</i>  |   |
| 4  | Transitional Basel III rules #   | N/A   |
| 5  | Post-transitional Basel III rules +  | Additional Tier 1   |
| 6  | Eligible at solo / group / solo and group  | Solo and group  |
| 7  | Instrument type (types to be specified by each jurisdiction)                                     | Undated Non-Cumulative Subordinated Additional Tier 1 Capital Securities  |
| 8  | Amount recognised in regulatory capital (currency in millions, as of most recent reporting date) | US\$500 million as at 24 January 2024   |
| 9  | Par value of instrument  | US\$500 million   |
| 10 | Accounting classification  | Equity - par value  |
| 11 | Original date of issuance  | 27 December 2023  |
| 12 | Perpetual or dated   | Perpetual   |
| 13 | Original maturity date   | No maturity   |
| 14 | Issuer call subject to prior supervisory approval  | Yes   |
| 15 | Optional call date, contingent call dates and redemption amount                                  | <ul style="list-style-type: none"> <li>- 27 December 2028 (First Call Date)</li> <li>- No fixed redemption date</li> <li>- Optional Redemption (on a designated date on 27 December 2028 or on any Distribution Payment Date thereafter), Tax or Regulatory Redemption are all subject to prior written consent of the HKMA and satisfying any conditions that the HKMA may impose at that time. Redemption amount will be the outstanding principal amount together (if appropriate) with distributions accrued to (but excluding) the date of redemption, subject to adjustment following the occurrence of a Non-Viability Event.</li> </ul> |
| 16 | Subsequent call dates, if applicable   | Any Distribution Payment Date after the First Call Date   |
|    | <i>Coupons / dividends</i>   |   |
| 17 | Fixed or floating dividend / coupon  | Fixed   |

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 5. US\$500 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 December 2023) (continued)

|    |   |  |
|----|---|--|
| 18 | Coupon rate and any related index                             | At a fixed rate of 6.30% per annum for the period from, and including, the Issue Date to, but excluding the First Call Date. On the First Call Date and each anniversary falling five years thereafter, the Distribution Rate will reset by reference to the then-prevailing five year U.S. Treasury Rate plus 242 bps per annum.<br><br>Any distributions are subject to there being no Mandatory Distribution Cancellation Event or Optional Distribution Cancellation Event.  |
| 19 | Existence of a dividend stopper                               | Yes  |
| 20 | Fully discretionary, partially discretionary or mandatory     | Fully discretionary  |
| 21 | Existence of step-up or other incentive to redeem             | No   |
| 22 | Non-cumulative or cumulative                                  | Non-cumulative   |
| 23 | Convertible or non-convertible                                | Non-convertible  |
| 24 | If convertible, conversion trigger(s)                         | N/A  |
| 25 | If convertible, fully or partially                            | N/A  |
| 26 | If convertible, conversion rate                               | N/A  |
| 27 | If convertible, mandatory or optional conversion              | N/A  |
| 28 | If convertible, specify instrument type convertible into      | N/A  |
| 29 | If convertible, specify issuer of instrument it converts into | N/A  |
| 30 | Write-down feature  | Yes  |
| 31 | If write-down, write-down trigger(s)                          | If a Non-Viability Event occurs and is continuing, the Issuer shall, by the provision of a Non-Viability Event Notice, irrevocably reduce the then prevailing principal amount of, and cancel any accrued but unpaid distribution in respect of, each Capital Security in whole or in part.<br><br>"Non-Viability Event" means the earlier of:<br>(a) the HKMA notifying the Issuer in writing that the HKMA is of the opinion that a write-off or conversion is necessary, without which the Issuer would become non-viable; and<br>(b) the HKMA notifying the Issuer in writing that a decision has been made by the government body, a government officer or other relevant regulatory body with the authority to make such a decision, that a public sector injection of capital or equivalent support is necessary, without which the Issuer would become non-viable. |

# CMB WING LUNG BANK LIMITED

## CCA: Main features of regulatory capital instruments (continued)

### 5. US\$500 million undated non-cumulative subordinated additional tier 1 capital securities (issued on 27 December 2023) (continued)

|    |   | (a)   |
|----|---|---|
|    |   | Quantitative / qualitative information  |
| 31 | If write-down, write-down trigger(s)  | <p>The Capital Securities may be written off, cancelled, converted or modified, or the form of the Capital Securities may be changed, in the exercise of any Hong Kong Resolution Authority Power under the Financial Institutions (Resolution) Ordinance (Cap. 628) of Hong Kong by the relevant Hong Kong Resolution Authority without prior notice and which may include (without limitation) and result in any of the following or some combination thereof:</p> <p>(a) the reduction or cancellation of all or a part of the principal amount of, or Distributions on, the Capital Securities;</p> <p>(b) the conversion of all or a part of the principal amount of, or Distributions on, the Capital Securities into shares or other securities or other obligations of the Issuer or another person (and the issue to or conferral on the holder of such shares, securities or obligations), including by means of an amendment, modification or variation of the terms of the Capital Securities; and</p> <p>(c) the amendment or alteration of the maturity of the Capital Securities or amendment or alteration of the amount of Distributions payable on the Capital Securities, or the date on which the Distributions become payable, including by suspending payment for a temporary period, or any other amendment or alteration of the terms and conditions of the Capital Securities.</p> |
| 32 | If write-down, full or partial  | Full or partial   |
| 33 | If write-down, permanent or temporary   | Permanent   |
| 34 | If temporary write-down, description of write-up mechanism  | N/A   |
| 35 | Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument in the insolvency creditor hierarchy of the legal entity concerned). | <p>Subordinate to the claims of:</p> <p>(a) all unsubordinated creditors of the Issuer (including its depositors);</p> <p>(b) creditors in respect of Tier 2 Capital Securities of the Issuer; and</p> <p>(c) all other Subordinated Creditors of the Issuer whose claims are stated to rank senior to the Capital Securities or rank senior to the Capital Securities by operation of law or contract.</p>   |
| 36 | Non-compliant transitioned features   | No  |
| 37 | If yes, specify non-compliant features  | N/A   |

# Regulatory treatment of capital instruments subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.

+ Regulatory treatment of capital instruments not subject to transitional arrangements provided for in Schedule 4H to the Banking (Capital) Rules.